PriceTargets.com logo

Scienture - SCNX Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $6.00
  • Forecasted Upside: 86.34%
  • Number of Analysts: 3
  • Breakdown:
  • 1 Sell Ratings
  • 1 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$3.22 As of 10/30/2026 05:00 PM ET
▼ -0.27 (-7.74%)

This chart shows the closing price for SCNX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Scienture Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for SCNX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for SCNX

Analyst Price Target is $6.00
▲ +86.34% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Scienture in the last 3 months. The average price target is $6.00, with a high forecast of $6.00 and a low forecast of $6.00. The average price target represents a 86.34% upside from the last price of $3.22.

This chart shows the closing price for SCNX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Hold

The current consensus among 3 contributing investment analysts is to hold stock in Scienture. This rating has held steady since February 2026, when it changed from a Sell consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/9/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/7/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
11/5/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
2/3/2026
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
5/4/2026
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
8/2/2026
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
10/1/2026
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
10/31/2026

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
10/23/2026Maxim GroupSet TargetBuy ➝ Buy$37.50 ➝ $6.00
10/2/2026Zacks ResearchUpgradeHold
9/21/2026Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
6/24/2026Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
3/27/2026Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
2/24/2026Maxim GroupInitiated CoverageBuy$37.50
12/29/2025Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
12/22/2025Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
12/15/2025Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
12/8/2025Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
12/2/2025Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
11/26/2025Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
10/8/2025Weiss RatingsReiterated RatingSell (D) ➝ Sell (D)
9/27/2025Weiss RatingsReiterated RatingSell (D) ➝ Sell (D)
(Data available from 10/31/2021 forward)

News Sentiment Rating

0.46 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/4/2026
  • 3 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/4/2026
  • 0 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/3/2026
  • 0 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/3/2026
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/2/2026
  • 1 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/1/2026
  • 0 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/1/2026
  • 2 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/31/2026

Current Sentiment

  • 2 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Scienture logo
Scienture Holdings, Inc. engages in the provision of health services and pharmaceutical products. It focuses on addressing underserved patients and indications through novel product concepts and innovation. The company was founded on July 15, 2005 and is headquartered in Lutz, FL.
Read More

Today's Range

Now: $3.22
Low: $3.17
High: $3.42

50 Day Range

MA: $6.33
Low: $2.77
High: $11.24

52 Week Range

Now: $3.22
Low: $2.64
High: $27.75

Volume

11,382 shs

Average Volume

410,976 shs

Market Capitalization

$5.67 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

3.34

Frequently Asked Questions

What sell-side analysts currently cover shares of Scienture?

The following Wall Street sell-side analysts have issued stock ratings on Scienture in the last year: Maxim Group, Wall Street Zen, Weiss Ratings, and Zacks Research.
View the latest analyst ratings for SCNX.

What is the current price target for Scienture?

0 Wall Street analysts have set twelve-month price targets for Scienture in the last year. Their average twelve-month price target is $6.00, suggesting a possible upside of 86.3%. Maxim Group has the highest price target set, predicting SCNX will reach $6.00 in the next twelve months. Maxim Group has the lowest price target set, forecasting a price of $6.00 for Scienture in the next year.
View the latest price targets for SCNX.

What is the current consensus analyst rating for Scienture?

Scienture currently has 1 sell rating, 1 hold rating and 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in SCNX, but not buy more shares or sell existing shares.
View the latest ratings for SCNX.

What other companies compete with Scienture?

Other companies that are similar to Scienture include MIRA Pharmaceuticals, Virios Therapeutics, Aytu BioPharma, Polyrizon and TherapeuticsMD. Learn More about companies similar to Scienture.

How do I contact Scienture's investor relations team?

Scienture's physical mailing address is 20 Austin Blvd., Commack, NY, 11725. The company's listed phone number is (800) 261-0281 and its investor relations email address is [email protected]. The official website for Scienture is www.scienture.com. Learn More about contacing Scienture investor relations.